Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmaceutics ; 15(3)2023 Mar 10.
Article in English | MEDLINE | ID: mdl-36986768

ABSTRACT

In the context of essential drug shortages, this article reports a proof of concept for the hospital preparation of a 2% propofol injectable nanoemulsion. Two processes for propofol were assessed: mixing propofol with the commercial Intralipid® 20% emulsion and a "de novo" process performed using separate raw materials (i.e., oil, water, and surfactant) and optimized for droplet size reduction with a high-pressure homogenizer. A propofol HPLC-UV stability-indicating method was developed for process validation and short-term stability. In addition, free propofol in the aqueous phase was quantified by dialysis. To envision routine production, sterility and endotoxin tests were validated. Only the "de novo" process using high-pressure homogenization gave satisfactory physical results similar to commercialized Diprivan® 2%. Both terminal heat sterilization processes (121 °C, 15 min and 0.22 µm filtration) were validated, but an additional pH adjustment was required prior to heat sterilization. The propofol nanoemulsion was monodisperse with a 160 nm mean droplet size, and no droplets were larger than 5µm. We confirmed that free propofol in the aqueous phase of the emulsion was similar to Diprivan 2%, and the chemical stability of propofol was validated. In conclusion, the proof of concept for the in-house 2% propofol nanoemulsion preparation was successfully demonstrated, opening the field for the possible production of the nanoemulsion in hospital pharmacies.

2.
J Cancer Educ ; 38(1): 285-291, 2023 02.
Article in English | MEDLINE | ID: mdl-34791602

ABSTRACT

Despite the growing use of chemotherapy drugs in resource-constrained settings, training opportunities on safe handling practices are lacking. This study's objectives were to develop and evaluate an e-learning training module on the safe handling of chemotherapy drugs to strengthen knowledge and practices in low- and middle-income countries (LMICs). The module's curriculum was developed using the Six-Step Approach for Curriculum Development for Medical Education. Asynchronous, self-paced, e-learning lessons within the module were created and uploaded onto a free online platform, Pharm-Ed. The study ran online from January to April 2021. Participant recruitment was done using convenience sampling through various channels (social media, communities of practice). Training module effectiveness was evaluated using knowledge assessments (a pre-test and post-test study design) and participant satisfaction. We developed a comprehensive e-learning module on the safe handling of chemotherapy drugs comprising 11 asynchronous, self-paced, e-learning lessons. Eighty-two participants (68% pharmacists and 17% pharmacy students) from 17 countries completed at least one lesson, with a total of 259 lessons completed. Evaluation of the different lessons showed significant improvements in theoretical knowledge (p < 0.01) in all except one lesson and a high degree of participant satisfaction. As the use of anti-cancer drugs in LMICs will continue to increase, this e-learning module is an effective means to address the lack of training opportunities on the safe handling of chemotherapies for healthcare workers in these countries. The module could be integrated into a multi-modal approach aimed at reducing occupational exposure and increasing patient safety in cancer care centers.


Subject(s)
Antineoplastic Agents , Computer-Assisted Instruction , Humans , Developing Countries , Antineoplastic Agents/therapeutic use , Health Personnel/education , Learning
3.
Sci Rep ; 10(1): 2850, 2020 02 18.
Article in English | MEDLINE | ID: mdl-32071330

ABSTRACT

One of the greatest challenges in the field of biofabrication remains the discovery of suitable bioinks that satisfy physicochemical and biological requirements. Despite recent advances in tissue engineering and biofabrication, progress has been limited to the development of technologies using polymer-based materials. Here, we show that a nucleotide lipid-based hydrogel resulting from the self-assembly of nucleotide lipids can be used as a bioink for soft tissue reconstruction using injection or extrusion-based systems. To the best of our knowledge, the use of a low molecular weight hydrogel as an alternative to polymeric bioinks is a novel concept in biofabrication and 3D bioprinting. Rheological studies revealed that nucleotide lipid-based hydrogels exhibit suitable mechanical properties for biofabrication and 3D bioprinting, including i) fast gelation kinetics in a cell culture medium and ii) shear moduli and thixotropy compatible with extruded oral cell survival (human gingival fibroblasts and stem cells from the apical papilla). This polymer-free soft material is a promising candidate for a new bioink design.


Subject(s)
Biocompatible Materials/chemistry , Lipids/chemistry , Nucleotides/chemistry , Printing, Three-Dimensional , Biocompatible Materials/pharmacology , Bioprinting/methods , Cell Survival/drug effects , Fibroblasts/drug effects , Humans , Hydrogels/chemistry , Hydrogels/pharmacology , Lipids/pharmacology , Nucleotides/pharmacology , Rheology , Stem Cells/drug effects , Tissue Engineering
4.
Drug Discov Today ; 24(1): 163-178, 2019 01.
Article in English | MEDLINE | ID: mdl-30391204

ABSTRACT

Recent developments in bioprinting have enabled an optimized formulation of bioinks by incorporating pharmaceuticals into cell-containing gel matrices. The proof-of-printability of a variety of forms has been provided, such as particles and fibers in the nanometric or micrometric range like dendrimers or micelles, although this is still lacking for some (liposomes for example). Resulting composite bioinks have the advantage of (i) improving cell growth and differentiation, (ii) delivering active molecules or (iii) improving mechanical properties of bioinks, printed scaffolds or the printing process. Improvement of these properties brings bioprinting one step forward toward clinical applications. Applications are reviewed for each field of improvements.


Subject(s)
Bioprinting , Animals , Dosage Forms , Drug Compounding , Humans , Ink , Nanostructures
SELECTION OF CITATIONS
SEARCH DETAIL
...